Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Avidity Biosciences Inc is a biotechnology business based in the US. Avidity Biosciences shares (RNA) are listed on the NASDAQ and all prices are listed in US Dollars. Avidity Biosciences employs 71 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$21.94|
|52-week range||$17.58 - $36.02|
|50-day moving average||$22.69|
|200-day moving average||$22.44|
|Wall St. target price||$46.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||2.57%|
|1 month (2021-09-24)||-6.36%|
|3 months (2021-07-26)||9.43%|
|6 months (2021-04-26)||-12.66%|
|1 year (2020-10-26)||-19.69%|
|2 years (2019-10-22)||N/A|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Revenue TTM||$9.2 million|
|Gross profit TTM||$-30,815,000|
|Return on assets TTM||-15.09%|
|Return on equity TTM||-26.2%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
There are currently 5.6 million Avidity Biosciences shares held short by investors – that's known as Avidity Biosciences's "short interest". This figure is 3.8% up from 5.4 million last month.
There are a few different ways that this level of interest in shorting Avidity Biosciences shares can be evaluated.
Avidity Biosciences's "short interest ratio" (SIR) is the quantity of Avidity Biosciences shares currently shorted divided by the average quantity of Avidity Biosciences shares traded daily (recently around 558970.66402379). Avidity Biosciences's SIR currently stands at 10.09. In other words for every 100,000 Avidity Biosciences shares traded daily on the market, roughly 10090 shares are currently held short.
However Avidity Biosciences's short interest can also be evaluated against the total number of Avidity Biosciences shares, or, against the total number of tradable Avidity Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avidity Biosciences's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Avidity Biosciences shares in existence, roughly 120 shares are currently held short) or 0.1357% of the tradable shares (for every 100,000 tradable Avidity Biosciences shares, roughly 136 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avidity Biosciences.
Find out more about how you can short Avidity Biosciences stock.
We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.
Avidity Biosciences, Inc. , a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.